{
    "2019-06-21": [
        [
            {
                "time": "",
                "original_text": "仿制药品目录建议清单出炉，受益股有哪些？",
                "features": {
                    "keywords": [
                        "仿制药",
                        "目录",
                        "建议清单",
                        "受益股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星医药：海外市场取得新突破，首个国产曲妥珠单抗获欧盟上市申请受理",
                "features": {
                    "keywords": [
                        "复星医药",
                        "海外市场",
                        "曲妥珠单抗",
                        "欧盟",
                        "上市申请"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【健康界产业周刊】青蒿素“引爆”资本市场 百济神州与新基“分手”",
                "features": {
                    "keywords": [
                        "健康界",
                        "青蒿素",
                        "资本市场",
                        "百济神州",
                        "新基",
                        "分手"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "东海证券发布医药行业中期策略：两维度布局",
                "features": {
                    "keywords": [
                        "东海证券",
                        "医药行业",
                        "中期策略",
                        "两维度布局"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "威高股份急挫逾4% 拟折让最多7%配售9170万股",
                "features": {
                    "keywords": [
                        "威高股份",
                        "急挫",
                        "配售",
                        "9170万股"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}